• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • Australia
      North America
      World
    Login

    Investing News NetworkYour trusted source for investing success

    • North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Medical Device Market
    Medical Device News
    Medical Device Stocks
    • Medical Device Market
    • Medical Device News
    • Medical Device Stocks

    Cutera Announces Expansion of FDA Indications for enlighten Laser Platform

    Gabrielle Lakusta
    Dec. 17, 2018 08:58AM PST
    Medical Device Investing

    CUTERA (Nasdaq:CUTR) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, today announces the U.S. Food and Drug Administration (FDA) approves clearance of an additional indication, for acne scars, on its premier enlighten® laser platform. As quoted in the press release: Dr. Neil Sadick, a world-renowned dermatologist, of Sadick Dermatology, …

    CUTERA (Nasdaq:CUTR) a leading provider of laser, light and other energy-based aesthetic systems for practitioners worldwide, today announces the U.S. Food and Drug Administration (FDA) approves clearance of an additional indication, for acne scars, on its premier enlighten® laser platform.

    As quoted in the press release:

    Dr. Neil Sadick, a world-renowned dermatologist, of Sadick Dermatology, NY, NY stated, “PICO Genesis FX elevates enlighten’s existing skin revitalization capabilities and introduces a fractional approach to treating acne scars, textural concerns and aging skin on all skin types. Its novel Micro Lens Array (MLA) treats the upper layers of the epidermis and dermis which generate collagen stimulation and remodeling of the skin. The expansion of this new fractional treatment means my patients will receive more efficacious results with little-to-no downtime for active lifestyles.”

    “The FDA clearance for acne scars represents another achievement for the enlighten platform and showcases Cutera’s on-going focus on innovation and clinical advancements in laser and light-based technology,” said James Reinstein, President and CEO of Cutera. “The system’s multiple wavelengths, dual pulse durations, and high power are all industry-leading features that offer practitioners a broad range of treatment settings and cleared indications. We will continue to develop technologies that advance the medical aesthetics industry and meet the needs of our customers and their patients.”

    Click here to read the full press release.

    nasdaq:cutr
    The Conversation (0)
    Go Deeper
    AI Powered
    Senior woman doing exercises alongside closeup of DNA.

    5 US Longevity and Anti-aging Stocks to Watch in 2025

    Pharma Outlook

    Pharma Outlook

    Latest News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Stocks

    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×